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Introduction
Acute respiratory distress syndrome (ARDS) is a clinical 
phenomenon [1] first described in 1967 [2]. A set of recalcitrant 
respiratory disorders had been observed in a variety of patients that did 
not respond to conventional therapies. ARDS is often a lethal disease. 
No new treatment modality has been devised, even though this is a 
wide spread problem and despite many efforts. A therapy for ARDS 
is proposed here based on an aerosol of a recombinant enzyme. The 
logistics behind such an approach is presented. 
ARDS and hyaline membranes
ARDS is not considered a specific disease, but a disorder in 
which there is acute lung dysfunction. It is associated with a variety 
of disorders including pneumonia, shock, sepsis, chemical injury, and 
trauma. It is one of the most severe forms of acute lung injury. Current 
figures estimate that 200,000 cases occur per year in the US, with a 
mortality rate of approximately 40% [3]. 
Since it is not a single disorder, a task force of pulmonary experts 
in 2011 developed the “Berlin Definition” [4]. They proposed three 
categories of ARDS based on degree of hypoxemia: mild, moderate 
and severe. These were associated with increasing mortality, and thus, 
will provide better informed clinical care and a more empirical patient 
evaluation.
One of the characteristic features of ARDS in the human is the 
development of hyaline membranes. This is a histologic feature of 
pulmonary tissue from ARDS patients. Using haematoxylin and eosin 
(H&E) staining, it is an amorphous pink acellular ribbon-like material 
that binds to the walls of alveoli. These structures are thought to prevent 
Abstract
Acute respiratory distress syndrome, also known as diffuse alveolar damage, is an acute injury to the lungs. 
Patients experience severe shortness of breath and require mechanical ventilation. It is not a specific disease, but 
an acute lung dysfunction associated with a variety of disorders: pneumonia, shock, sepsis, and trauma. A similar 
lesion occurs in newborn infants, called hyaline disease of the newborn. It occurs in premature babies and has the 
same pathophysiological mechanism as acute respiratory distress syndrome. Hyaline membranes are a pathologic 
feature of acute respiratory distress syndrome, consisting of basophilic structures that coat alveolar surfaces. They 
prevent oxygen exchange and are the basis of the lethality of this disorder. The syndrome is associated with very 
high levels of hyaluronan in broncho-alveolar lavage specimens. We postulate that the hyaline membranes of acute 
respiratory distress syndrome are hyaluronan-rich structures associated with serum hyaluronan-binding proteins such 
as fibrinogen and fibrin. Potent infectious influenza viruses are recurrent pandemics and potential terrorist threats. 
Lethality of influenza infection correlates with the presence of hyaline membranes. Installation of hyaluronidase as an 
aerosol would provide a new treatment for acute respiratory respiratory distress syndrome, for which there has been no 
new treatment in 45 years. The pig is the only species other than humans that develop hyaline membranes. Employing 
this treatment in the porcine model would provide a direct test of the hypothesis.
Hyaluronidase: A Potential New Treatment for Acute Respiratory Distress 
Syndrome
C LeBlanc and R Stern*
Department of Basic Biomedical Sciences, Touro College of Osteopathic Medicine, New York, USA
air exchange between alveoli and capillaries imbedded in alveolar walls. 
The clinical and pathological features closely resemble those observed 
in premature infants, referred to as neonatal respiratory distress 
syndrome (NRDS). Similar structures occur in the lungs of preterm 
NRDS infants.
Neonatal respiratory distress syndrome
NRDS, formerly known as hyaline membrane disease of the new-
born, is a serious respiratory disorder in the preterm infant [5]. The 
syndrome is attributed to a deficiency in surfactant production and 
structural immaturity of the lungs. It is the most common cause of 
death in these preterm infants. An animal model has been obtained in 
premature monkeys [6,7] that closely resembles the human disorder. It 
is assumed that a similar pathophysiological mechanism is involved.
Influenza, past influenza epidemics and pandemics
Influenza is a negative stranded RNA virus. There have been many 
virulent pandemics of influenza in the past. The most notorious is the 
Spanish flu of 1918-1919. More people died of Spanish influenza in a 
single year than in four-years of WWI, with a mortality rate of about 
40%. Approximately 3% of the world’s population died, making it one 
of the deadliest natural disasters in human history, with more deaths 
than in the Black Death-Bubonic Plague of 1347 to 1351. More recent 
epidemics include severe acute respiratory syndrome (SARS) of 2002-
2003, and H1N1, known as the Swine flu of 2009, with 18,000 deaths 
worldwide.
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Terrorist threats and anti-terrorist measures
Genetically engineered influenza viruses have the potential of 
becoming a basis of biological warfare and a major terrorist threat. 
Preparation of such viruses for use in biological warfare is relatively 
straight-forward. A high school biology class could accomplish this 
bit of molecular genetics. Thus, it is absolutely necessary to become 
prepared for such events, and to evolve protective strategies for such 
contingencies. The present hypothesis provides precisely such a 
measure. The hyaluronidase aerosol would be a universally effective 
treatment modality, instantly available for all victims of such a potential 
catastrophy.
Animal models for influenza infections and ARDS
A number of animal models are available for studying influenza 
infections as well as for ARDS. The ferret reflects closely most features 
of the human disease. They are exquisitely susceptible to infection with 
human influenza viruses, express similar symptoms, and are the ideal small 
animal model for research [8,9]. They also respond in a fashion similar to 
humans the various immune responses including vaccination strategies. 
Other animal models include rats, hamsters, and guinea pigs. 
However none of these animals develop the hyaline membranes that 
characterize ARDS in humans. The mortality of influenza infections 
in humans correlates with hyaline membrane formation. Those that 
succumb to infection have hyaline membranes, those that survive do 
not on a nearly one to one basis (personal observations, RS). There is 
only one experimental animal that does develop hyaline membranes, 
and that is the pig [10]. No other influenza non-primate model does 
so. Hyaline membranes in the pig have pathologic and histochemical 
features identical to that in the human. There is one exception, and that 
is the animal model for NRDS, the premature monkey [7].
The Mendelson syndrome for ARDS and hyaline 
membrane formation
A major problem for the use of pigs in studying influenza-derived 
ARDS and hyaline membranes is human infectivity. Pigs and humans 
are susceptible to the same viruses. Influenza viruses exchange antigenic 
epitopes easily and rapidly. Virulent infections may arise, even when 
attenuated viruses are utilized initially. For this reason, a Biosafety 
Laboratory-3 (BSL-3) facility is required. This is extremely expensive, 
and very cumbersome for animal manipulation. Even small pig models 
such as Yucatan pigs, micro-pigs, or young piglets present difficulties. 
For this reason, a non-infective ARDS model is preferable. 
The Mendelson syndrome, the aspiration of gastric contents into 
the lungs elicits hyaline membrane formation [11]. Inoculation of 0.1 
M HCl into the pig through a bronchial tube reproduces the syndrome 
rapidly and easily [10]. This provides a convenient non-infectious 
alternative to influenza infection for studying hyaline membranes.
Hyaluronan
Hyaluronan (HA, hyaluronic acid) is a straight chain 
glycosaminoglycan (GAG) of the extracellular matrix (ECM) [12-14]. 
It is the major component of the ECM, particularly prominent during 
development, regeneration and repair, and whenever there is rapid 
tissue turnover. HA characterizes the stem cell niche [15]. HA is the 
only GAG that that has no secondary modifications. It is not sulfated, 
nor does it undergo epimerization reactions. HA also characterizes 
tissues with infections and other inflammatory responses [16,17]. 
Evidence suggests that hyaline membranes are HA-rich structures. 
Hyaluronan in ARDS
There are major concentrations of HA that occur in ARDS [2]. 
Samples taken from broncho-alveolar lavage (BAL) specimens of ARDS 
patients have markedly elevated HA levels. Less than 20 µg/ml of HA 
occur in BAL samples from patients with normal lungs, while in two 
studies, levels of 353 µg/ml and 515 µg/ml were observed, representing 
20 to 25 times normal levels [18,19]. Increased HA deposition also occurs 
in the premature monkey model of ARDS [7]. An excellent review of 
the role of HA in acute lung injury is available [20]. Such data suggests 
that hyaline membranes contain HA. There are copious levels of HA 
in the inflamed lung, together with several HA-binding proteins. Such 
proteins are present in plasma and in tissue exudates, which are filtrates 
of plasma. Prominent among such HA-binding proteins are fibrinogen, 
fibrin and its split products [21-23], and inter-alpha-inhibitor protein 
family [24]. The latter not only stabilizes ECM structures such as 
hyaline membranes, but is also hyaluronidase inhibitors [25]. All of 
these features contribute to the argument that hyaline membranes are 
stabilized HA-rich structures that are protected from the surrounding 
catabolic activities that characterize inflammation.
Suppression of HA synthesis ameliorates acute lung 
injuries
Further evidence for the role of HA in acute lung injury comes 
from inhibitor studies. The drug 4-methylumbelliferone  (4-MB) is a 
potent inhibitor of hyaluronan synthesis [26]. Administered orally in 
mice, it suppresses the intensity of the inflammatory response following 
acute lung injury [27,28]. This provides additional evidence that HA 
is associated with the inflammation in acute lung injury. The 4-MB is 
available as a therapeutic in Europe, but not yet in the U.S.
Hyaline
The term “hyaline” used by Pathologists, has no biochemical 
equivalent. It was described 150 years ago by German pathologists 
before there was anything such thing as biochemistry. It was observed 
by H&E staining, and various special stains, all fall-outs from the 
aniline dye industry. A hyaline substance appears glassy and pink after 
staining and is acellular. There have been no attempts to analyse hyaline 
biochemically.
Hyaline therefore is an ambiguous term. We postulate that hyaline 
staining may refer to HA-rich structures. This can be confirmed by 
preincubation of tissue sections with a hyaluronidase. The proviso is 
that most hyaluronidases are also chondroitinases that also degrade 
chondroitin sulphate, albeit at a much slower rate. There is one 
bacterial enzyme that is HA-specific, the one derived from Streptomyces 
hyaluronlyticus. Many histochemical studies have failed to use 
this enzyme. A step towards evaluating the HA content of hyaline 
membranes in Pathology specimens would be to demonstrate loss of 
staining of tissue sections following S. hyaluronlyticus incubation.
Hyaluronidases
Hyaluronidases are the hydrolase enzymes that catabolize HA 
throughout the body of vertebrate. They are hydrolases rather than 
the eliminases that occur in prokaryotes. The intrinsic difficulty in 
measuring such hydrolases was the reason these were long neglected 
enzymes [29]. This is in marked contrast with the bacterial enzyme 
activity that can easily be followed by spectrophotometry. There are six 
hyaluronidase-like sequences in the human genome, tightly clustered, 
three each on chromosomes 3p and 7q [30,31]. Of these, two are 
acid-active and are prominent in HA degradation in somatic tissues, 
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HYAL1 and HYAL2. Both of these are present in the 3p cluster. The 
third hyaluronidase-like sequence in this cluster is not associated with 
a detectable enzyme activity. In the 7q gene cluster, one is a pseudogene, 
transcribed but not translated. Another is a chondroitinase [32,33]. 
pH-20 appears to be the only hyaluronidase enzyme active at neutral 
pH. It is associated with sperm and is involved in fertilization. The 
latter enzyme has been commercialized in a recombinant form, and is 
available as Hylenex® [34,35], a product of Halozyme Therapeutics, San 
Diego, CA. A polyethylene-glycol cross-linked (PEGylated) form of the 
enzyme is also being produced. The latter formulation has considerably 
greater half-life following its administration.
Aerosols as drug treatment modalities
Hyaluronidase as a therapeutic agent administered as a nasal 
spray for pulmonary delivery has not been attempted previously. The 
pulmonary administration of medications through nasal aerosols has 
been in use for decades. Corticosteroid inhalants are employed to 
alleviate asthma and for patients with chronic obstructive pulmonary 
disease [36]. There are many other successful examples of such uses. 
Nano particles have been used for pulmonary drug delivery [37,38], 
as well as spray-dried particles [39]. Enzymes have been utilized 
previously as aerosol treatments. One of these is Pulmozyme®, a cocktail 
of human recombinant deoxyribonuclease (DNAases or rhDNase) in 
the management of cystic fibrosis. A precedent exists therefore for the 
use of a hyaluronidase such as Hylenex® as a mode of treatment. This has 
the potential of becoming a new and effective treatment for ARDS.
Serious provisos and potential drawbacks
The lung is an HA-rich structure, and even more so when there 
is inflammation [40,16]. A serious drawback to our hypothesis, that 
hyaluronidase can be a therapeutic measure for the treatment of 
ARDS, is that it may make the condition even worse. Administered 
enzyme could fragment existing HA-rich structures of the lung, 
and thus intensify disease. Endogenous HA and its HA fragment 
degradation products would flood the lung. Small HA polymers are 
highly angiogenic, inflammatory, and immune-stimulatory [41,42]. 
HA fragments are themselves not only intrinsically inflammatory, 
but also induce inflammatory cytokine expression [43,44]. It is 
conceivable that the hyaluronidase enzyme treatment may intensify 
rather than abate the inflammatory reaction. Thus there may be 
serious consequences of hyaluronidase administration. This is a 
situation that would be readily apparent in the porcine model using 
the Mendelson syndrome. Titration of the volume of the HCl solution 
administered in the pig model may be able to reproduce the three 
levels of severity of ARDS: mild, moderate and severe. The levels 
of hyaluronidase aerosol provided could perhaps be modulated 
to maximize clinical response and also to avoid potential adverse 
reactions. 
Conclusion
It is postulated that the hyaline membranes in patients with ARDS 
are HA-rich structures. This is an insoluble complex of HA together 
with plasma HA-binding proteins that adhere to inflamed alveoli 
preventing oxygen exchange. A recombinant form of the human 
hyaluronidase enzyme PH20 can be administered as an aerosol to 
ARDS patients. This will degrade hyaline membranes in these damaged 
lungs and increase survival of such patients. It may become the first 
effective treatment modality in several decades for ARDS in adults and 
may also be effective for NRDS in premature infants. A porcine model 
for ARDS, employing bronchial delivery of 0.1 M HCl to the lungs, 
makes it possible to test this hypothesis.
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